Address: Janssen-Cilag, Department of Johnson-Johnson S.E., Bulevar Mihajla Pupina 248, 11000 Belgrade, Serbia
The international company Janssen-Cilag was established in 1994 as a result of merger of two Johnson&Johnson divisions, viz. Cilag (short for Chemische Industrie-Labor AG) and Janssen Pharmaceutica.
Janssen-Cilag that accounts for the development of more than 80 original drugs has twice received the prestigious international Galenic Prize for pharma achievements (for Rispolept in 1996; for Velcade in 2006). The company’s main fields are psychiatry, neurology, and gastroenterology; besides, it specializes in pain and mycose therapies.
The company will develop sustainable, integrated health care solutions by working with patients, physicians and other stakeholders, based on partnerships of trust and transparency. It will continue to invest in our people to realize their personal growth and to build our leaders of the future.
Janssen makes a big difference in the health and well-being of people every day. The company is operational in all countries thoughout Europe employing more than 6,000 people.
Products and services
We will focus our energy on five major therapeutic areas of unmet need:
– Neuroscience (schizophrenia, dementia, pain …),
– Infectious Diseases (HIV/AIDS, Hepatitis C, tuberculosis, …),
– Oncology (multiple myeloma, prostate cancer, …),
– Immunology (psoriasis, …),
– Metabolism (diabetes, …).